ABCA3 | ATP-binding cassette, sub-family A (ABC1), member 3 | Disease related genes Plasma proteins Potential drug targets Predicted membrane proteins Transporters
| | | | | Tissue enhanced |
AC090616.2 | Uncharacterized protein | Predicted secreted proteins
| | | | | Tissue enhanced |
ADAMTS8 | ADAM metallopeptidase with thrombospondin type 1 motif, 8 | Cancer-related genes Enzymes Plasma proteins Predicted secreted proteins
| | | | | Tissue enhanced |
AGBL1 | ATP/GTP binding protein-like 1 | Disease related genes Enzymes Potential drug targets
| | | | | Tissue enhanced |
AL353354.2 | | Predicted secreted proteins
| | | | | Tissue enhanced |
AL591684.1 | Protein LOC100996760 | | | | | | Tissue enhanced |
AL603965.1 | Protein LOC100996760 | | | | | | Tissue enhanced |
ALOX15 | Arachidonate 15-lipoxygenase | Disease related genes Enzymes Potential drug targets
| | | | | Tissue enhanced |
ALPL | Alkaline phosphatase, liver/bone/kidney | Cancer-related genes Disease related genes Enzymes Plasma proteins Potential drug targets Predicted membrane proteins Predicted secreted proteins
| | | | | Tissue enhanced |
ANKRD29 | Ankyrin repeat domain 29 | Predicted membrane proteins
| | | | | Tissue enhanced |
ATP13A4 | ATPase type 13A4 | Disease related genes Predicted membrane proteins
| | | | | Tissue enhanced |
C11orf16 | Chromosome 11 open reading frame 16 | | | | | | Tissue enhanced |
C16orf89 | Chromosome 16 open reading frame 89 | Predicted membrane proteins Predicted secreted proteins
| | | | | Tissue enhanced |
C1orf110 | Chromosome 1 open reading frame 110 | | | | | | Tissue enhanced |
C1orf116 | Chromosome 1 open reading frame 116 | | | | | | Tissue enhanced |
C5orf38 | Chromosome 5 open reading frame 38 | | | | | | Tissue enhanced |
C6orf223 | Chromosome 6 open reading frame 223 | | | | | | Tissue enhanced |
CASS4 | Cas scaffolding protein family member 4 | Cytoskeleton related proteins Plasma proteins
| | | | | Tissue enhanced |
CAV1 | Caveolin 1, caveolae protein, 22kDa | Cancer-related genes Disease related genes Potential drug targets Predicted membrane proteins Transporters
| | | | | Tissue enhanced |
CCL18 | Chemokine (C-C motif) ligand 18 (pulmonary and activation-regulated) | Cancer-related genes Plasma proteins Predicted secreted proteins
| | | | | Tissue enhanced |
CLEC14A | C-type lectin domain family 14, member A | Predicted membrane proteins
| | | | | Tissue enhanced |
CNTN6 | Contactin 6 | Predicted membrane proteins
| | | | | Tissue enhanced |
COL13A1 | Collagen, type XIII, alpha 1 | Predicted membrane proteins
| | | | | Tissue enhanced |
COL6A5 | Collagen, type VI, alpha 5 | Disease related genes Predicted secreted proteins
| | | | | Tissue enhanced |
COL6A6 | Collagen, type VI, alpha 6 | Predicted secreted proteins
| | | | | Tissue enhanced |
CPAMD8 | C3 and PZP-like, alpha-2-macroglobulin domain containing 8 | Predicted secreted proteins
| | | | | Tissue enhanced |
CRTAC1 | Cartilage acidic protein 1 | Plasma proteins Predicted secreted proteins
| | | | | Tissue enhanced |
CSF2 | Colony stimulating factor 2 (granulocyte-macrophage) | Cancer-related genes Predicted secreted proteins
| | | | | Tissue enhanced |
CSF3 | Colony stimulating factor 3 (granulocyte) | Cancer-related genes Plasma proteins Predicted secreted proteins
| | | | | Tissue enhanced |
CTD-2600O9.1 | Uncharacterized protein LOC388282 | | | | | | Tissue enhanced |
CTD-3214H19.16 | | | | | | | Tissue enhanced |
CXCL17 | Chemokine (C-X-C motif) ligand 17 | Predicted secreted proteins
| | | | | Tissue enhanced |
CYP2F1 | Cytochrome P450, family 2, subfamily F, polypeptide 1 | Enzymes Predicted secreted proteins
| | | | | Tissue enhanced |
CYP4B1 | Cytochrome P450, family 4, subfamily B, polypeptide 1 | Enzymes Predicted membrane proteins
| | | | | Tissue enhanced |
DCSTAMP | Dendrocyte expressed seven transmembrane protein | Predicted membrane proteins
| | | | | Tissue enhanced |
DKK2 | Dickkopf WNT signaling pathway inhibitor 2 | Predicted secreted proteins
| | | | | Tissue enhanced |
EFCC1 | EF-hand and coiled-coil domain containing 1 | | | | | | Tissue enhanced |
EMP2 | Epithelial membrane protein 2 | Predicted membrane proteins
| | | | | Tissue enhanced |
ESYT3 | Extended synaptotagmin-like protein 3 | Predicted membrane proteins
| | | | | Tissue enhanced |
FBN3 | Fibrillin 3 | Predicted secreted proteins
| | | | | Tissue enhanced |
FIGF | C-fos induced growth factor (vascular endothelial growth factor D) | Cancer-related genes Plasma proteins Predicted secreted proteins RAS pathway related proteins
| | | | | Tissue enhanced |
FMO2 | Flavin containing monooxygenase 2 (non-functional) | Enzymes Predicted secreted proteins
| | | | | Tissue enhanced |
FOLR1 | Folate receptor 1 (adult) | Disease related genes Potential drug targets Predicted membrane proteins Transporters
| | | | | Tissue enhanced |
GDF10 | Growth differentiation factor 10 | Plasma proteins Predicted secreted proteins
| | | | | Tissue enhanced |
GGTLC3 | Gamma-glutamyltransferase light chain 3 | | | | | | Tissue enhanced |
GPR116 | G protein-coupled receptor 116 | G-protein coupled receptors Plasma proteins Predicted membrane proteins
| | | | | Tissue enhanced |
GPRC5A | G protein-coupled receptor, family C, group 5, member A | G-protein coupled receptors Predicted membrane proteins
| | | | | Tissue enhanced |
GPRIN2 | G protein regulated inducer of neurite outgrowth 2 | | | | | | Tissue enhanced |
GRAMD2 | GRAM domain containing 2 | Predicted membrane proteins
| | | | | Tissue enhanced |
HHIP | Hedgehog interacting protein | Predicted membrane proteins Predicted secreted proteins
| | | | | Tissue enhanced |